会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 75. 发明申请
    • ASYMMETRIC SYNTHESIS OF ROCAGLAMIDES VIA ENANTIOSELECTIVE PHOTOCYCLOADDITION MEDIATED BY CHIRAL BRONSTED ACIDS
    • 不对称合成通过由CHIRAL BRONSTED ACIDS介导的选择性光合作用的聚酰胺
    • WO2007139749A3
    • 2008-11-27
    • PCT/US2007012062
    • 2007-05-21
    • UNIV BOSTONPORCO JOHN A JRGERARD BAUDOUIN
    • PORCO JOHN A JRGERARD BAUDOUIN
    • C07D311/00C07D307/00C07D307/93
    • C07D317/12C07D307/93C07D317/72C07D493/08C07D493/10
    • The present invention provides a new strategies for the synthesis of compounds of the rocaglamide family and related natural products. The synthetic approach generally involves photochemical generation of an oxidopyrylium species from a 3-hydroxychromone derivative followed by an enantioselective 1,3-dipolar cycloaddition of the oxidopyrylium species to a dipolarophile in the presence of a TADDOL derivative. This approach can be used for the formation of adducts containing an aglain core structure. Methods of the conversion of aglain core structures to aglain, rocaglamide and forbaglin ring systems are also provided. The present invention also relates to the use of rocaglamide/aglain/forbaglin derivatives for the manufacture of medicaments for use in the treatment of cancer or cancerous conditions, disorders associated with cellular hyperproliferation, or NF-?B-dependent conditions.
    • 本发明提供了合成罗卡酰胺家族化合物和相关天然产物的新策略。 合成方法通常涉及在3-羟基色酮衍生物中光化学生成氧化吡啶鎓物质,随后在TADDOL衍生物存在下,将氧化吡啶类物质对映选择性的1,3-偶极环加成偶极嗜酸物质。 该方法可用于形成含有阿格林核心结构的加合物。 还提供了将阿格林核心结构转化为阿格林,罗卡酰胺和巴格林环系统的方法。 本发明还涉及用于制造用于治疗癌症或癌症病症的药物,与细胞过度增生相关的病症或NF-κB依赖性病症的药物的罗格列酰胺/阿格林/用于囊霉素衍生物的用途。
    • 76. 发明申请
    • MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY, CRYSTALLINE FORMS AND PROCESS
    • 化合物受体活性的调节剂,结晶形式和过程
    • WO2008014381A2
    • 2008-01-31
    • PCT/US2007074438
    • 2007-07-26
    • SQUIBB BRISTOL MYERS COYANG MICHAEL GCHERNEY ROBERT JEASTGATE MARTIN GMUSLEHIDDINOGLU JALEPRASAD SIVA JOSYULAXIAO ZILI
    • YANG MICHAEL GCHERNEY ROBERT JEASTGATE MARTIN GMUSLEHIDDINOGLU JALEPRASAD SIVA JOSYULAXIAO ZILI
    • C07D207/273A61K31/4025C07D403/12
    • C07D403/12C07D207/273C07D317/72Y02P20/55
    • The present invention provides a novel antagonist or partial agonists/antagonists of MCP-1 receptor activity: N-((1R,2S,5R)-5-(isopropyl(methyl)amino)-2-((S)-2-oxo-3-(6-(trifluoromethyl)quinazolin-4-ylamino)pyrrolidin-1-yl)cyclohexyl)acetamide, or a pharmaceutically acceptable salt, solvate or prodrug, thereof, having an unexpected combination of desirable pharmacological characteristics. Crystalline forms of the present invention are also provided. Pharmaceutical compositions containing the same and methods of using the same as agents for the treatment of inflammatory diseases, allergic, autoimmune, metabolic, cancer and/or cardiovascular diseases is also an objective of this invention. The present disclosure also provides a process for preparing compounds of Formula (I), including N-((1R,2S,5R)-5-(isopropyl(methyl)amino)-2-((S)-2-oxo-3-(6-(trifluoromethyl)quinazolin-4-ylamino)pyrrolidin-1-yl)cyclohexyl)acetamide: wherein R 1 , R 8 , R 9 , R 10 , and structure (a) are as described herein. Compounds that are useful intermediates of the process are also provided herein.
    • 本发明提供MCP-1受体活性的新型拮抗剂或部分激动剂/拮抗剂:N - ((1R,2S,5R)-5-(异丙基(甲基)氨基)-2 - ((S) -3-(6-(三氟甲基)喹唑啉-4-基氨基)吡咯烷-1-基)环己基)乙酰胺或其药学上可接受的盐,溶剂合物或前药,具有期望的药理学特征的意想不到的组合。 还提供了本发明的结晶形式。 含有该组合物的药物组合物以及使用其作为治疗炎性疾病,过敏性,自身免疫性,代谢性,癌症和/或心血管疾病的药剂的方法也是本发明的目的。 本公开还提供制备式(I)化合物的方法,包括N - ((1R,2S,5R)-5-(异丙基(甲基)氨基)-2 - ((S)-2-氧代-3 - (6-(三氟甲基)喹唑啉-4-基氨基)吡咯烷-1-基)环己基)乙酰胺其中R 1,R 8,R 9, / SUP>,R 10和结构(a)如本文所述。 本文还提供了该方法有用中间体的化合物。